Summary of Study ST003045
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001895. The data can be accessed directly via it's Project DOI: 10.21228/M8S14W This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003045 |
| Study Title | Proteomic and metabolomic signatures of rectal tumor discriminate patients with different responses to preoperative radiotherapy |
| Study Summary | Background: Neoadjuvant radiotherapy (neo-RT) is widely used in locally advanced rectal cancer (LARC) as a component of radical treatment. Despite the advantages of neo-RT, which typically improves outcomes in LARC patients, the lack of reliable biomarkers that predict response and monitor the efficacy of therapy, can result in the application of unnecessary aggressive therapy affecting patients’ quality of life. Hence, the search for molecular biomarkers for assessing the radio responsiveness of this cancer represents a relevant issue. Methods: Here, we combined proteomic and metabolomic approaches to identify molecular signatures, which could discriminate LARC tumors with good and poor responses to neo-RT. Results: The integration of data on differentially accumulated proteins and metabolites made it possible to identify disrupted metabolic pathways and signaling processes connected with response to irradiation, including ketone bodies synthesis and degradation, purine metabolism, energy metabolism, degradation of fatty acid, amino acid metabolism, and focal adhesion. Moreover, we proposed multi-component panels of proteins and metabolites which could serve as a solid base to develop biomarkers for monitoring and predicting the efficacy of preoperative RT in rectal cancer patients. Conclusions: We proved that an integrated multi-omic approach presents a valid look at the analysis of the global response to cancer treatment from the perspective of metabolomic reprogramming. |
| Institute | Institute of Bioorganic Chemistry Polish Academy of Sciences |
| Last Name | Wojakowska |
| First Name | Anna |
| Address | Noskowskiego 12/14, Poznan, Greater Poland, 61-704, Poland |
| astasz@ibch.poznan.pl | |
| Phone | +48616653051 |
| Submit Date | 2024-01-17 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | cdf |
| Analysis Type Detail | GC-MS |
| Release Date | 2024-02-08 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO003153 |
| Collection Summary: | Tissue samples were taken from 24 LARC patients diagnosed with adenocarcinoma and treated at Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch. All patients were given neo-RT in a total dose of 39-54Gy. Tissue samples were collected between 2012 and 2014, directly during a standard surgical treatment; resected tissue samples were immediately frozen and kept at -80 °C until analysis performed in 2020. The histology of three tissue slices (from the edges and center of the studied tissue sample) was assessed by an experienced pathologist for the percentage of tumor cells in each case. TRG assessed routinely in resected tumors reflected the area of residual tumor cells compared to the fibrotic area: TRG0 - complete response/no residual tumor, TRG1 - 10% of residual tumor, TRG2 - 10-50% of residual tumor, and TRG3 - >50% of residual tumor. Depending on the response to the treatment and the presence of tumor cells, collected samples were classified into two groups: good responders (GR) – 12 patients with RT-sensitive tumors (TRG 0-1), and poor responders (PR) - 12 patients with RT-resistant tumors (TRG 2-3). |
| Sample Type: | Rectum |
